Polymorphisms of the BRAF gene predispose males to malignant melanoma

Journal of Carcinogenesis

Volumn 2, Issue , 2003, Pages

  Meyer, Peter ^a,b   Sergi, Consolato ^c   Garbe, Claus ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b Genefinder Technologies Beteiligungs GmbH   (Germany)

^c BRISTOL ROYAL INFIRMARY   (United Kingdom)

Author keywords

Association study; BRAF; Familial; Gene; Melanoma; Molecular genetics; Predisposition; Single Nucleotide Polymorphism (SNP); Sporadic

Indexed keywords

PROTEIN SERINE THREONINE KINASE;

ADULT; ANALYSIS OF VARIANCE; ARTICLE; CANCER INCIDENCE; CONTROLLED STUDY; EVIDENCE BASED MEDICINE; FEMALE; FREQUENCY ANALYSIS; GENE LOCUS; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC SUSCEPTIBILITY; GERM LINE; GERMANY; HAPLOTYPE; HUMAN; HUMAN TISSUE; INHERITANCE; MAJOR CLINICAL STUDY; MALE; MELANOGENESIS; MELANOMA; PREVALENCE; RISK FACTOR; SEX DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; SOMATIC MUTATION;

EID: 2942625415     PISSN: 14773163     EISSN: None     Source Type: Journal    
DOI: 10.1186/1477-3163-2-7     Document Type: Article

References (38)

1. Hall HI, Miller DR, Rogers JD, Bewerse B: Update on the incidence and mortality from melanoma in the United States. J Am Acad Dermatol 1999, 40(1):35-42.
2. American Cancer Society: Cancer Facts and Figures 2002. 2003 [http://www.cancer.org/downloads/STT/Cancer Facts&Figures2002TM.pdf].
3. Beddingfield FC III: The melanoma epidemic: res ipsa loquitur. Oncologist 2003, 8(5):459-465.
4. Hussussian CJ, Struewing JP, Goldstein AM, Higgins PA, Ally DS, Sheahan MD, Clark WH Jr, Tucker MA, Dracopoli NC: Germline p16 mutations in familial melanoma. Nat Genet 1994, 8(1):15-21.
5. Kamb A, Shattuck-Eidens D, Eeles R, Liu Q, Gruis NA, Ding W, Hussey C, Tran T, Miki Y, Weaver-Feldhaus J: Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus. Nat Genet 1994, 8(1):23-26.
6. Soufir N, Avril MF, Chompret A, Demenais F, Bombled J, Spatz A, Stoppa-Lyonnet D, Benard J, Bressac-de Paillerets B: Prevalence of p16 and CDK4 germline mutations in 48 melanoma-prone families in France. The French Familial Melanoma Study Group. Hum Mol Genet 1998, 7(2):209-216.
7. Bataille V: Genetic Epidemiology of Melanoma. Eur J Cancer 2003, 39(10):1341-1347.
8. Hutchinson PE, Osborne JE, Lear JT, Smith AG, Bowers PW, Morris PN, Jones PW, York C, Strange RC, Fryer AA: Vitamin D receptor polymorphisms are associated with altered pro-gnosis in patients with malignant melanoma. Clin Cancer Res 2000,6(2):498-504.
9. Ichii-Jones F, Lear JT, Heagerty AH, Smith AG, Hutchinson PE, Osborne J, Bowers B, Jones PW, Davies E, Ollier WE, Thomson W, Yengi L, Bath J, Fryer AA, Strange RC: Susceptibility to melanoma: influence of skin type and polymorphism in the melanocyte stimulating hormone receptor gene. J Invest Dermatol 1998, 111(2):218-221.
10. Valverde P, Healy E, Sikkink S, Haldane F, Thody AJ, Carothers A, Jackson IJ, Rees JL: The Asp84Glu variant of the melanocortin 1 receptor (MC1R) is associated with melanoma. Hum Mol Genet 1996, 5(10):1663-1666.
11. Lafuente A, Molina R, Palou J, Castel T, Moral A, Trias M: Phenotype of glutathione S-transferase Mu (GSTM1) and susceptibility to malignant melanoma. MMM group. Multi-disciplinary Malignant Melanoma Group. Br J Cancer 1995, 72(2):324-326.
12. Strange RC, Ellison T, Ichii-Jones F, Bath J, Hoban P, Lear JT, Smith AG, Hutchinson PE, Osborne J, Bowers B, Jones PW, Fryer AA: Cytochrome P450 CYP2D6 genotypes: association with hair colour, Breslow thickness and melanocyte stimulating hormone receptor alleles in patients with malignant melanoma. Pharmacogenetics 1999, 9(3):269-276.
13. Shahbazi M, Pravica V, Nasreen N, Fakhoury H, Fryer AA, Strange RC, Hutchinson PE, Osborne JE, Lear JT, Smith AG, Hutchinson IV: Association between functional polymorphism in EGF gene and malignant melanoma. Lancet 2002, 359(9304):397-401.
14. Pollock PM, Trent JM: The genetics of cutaneous melanoma. Clin Lab Med 2000, 20(4):667-690.
15. Aitken J, Welch J, Duffy D, Milligan A, Green A, Martin N, Haywar N: CDKN2A variants in a population-based sample of Queensland families with melanoma. J Natl Cancer Inst 1999, 91(5):446-452.
16. Tsao H, Zhang X, Kwitkiwski K, Finkelstein DM, Sober AJ, Haluska FG: Low prevalence of germline CDKN2A and CDK4 mutations in patients with early-onset melanoma. Arch Dermatol 2000, 136(9):1118-1122.
17. Kruglyak L: Prospects for whole-genome linkage disequilibrium mapping of common disease genes. Nat Genet 1999, 22(2):139-144.
18. Bansal A, van den BD, Kammerer S, Honisch C, Adam G, Cantor CR, Kleyn P, Braun A: Association testing by DNA pooling: an effective initial screen. Proc Natl Acad Sci U S A 2002, 99(26):16871-16874.
19. Mohlke KL, Erdos MR, Scott LJ, Fingerlin TE, Jackson AU, Silander K, Hollstein P, Boehnke M, Collins FS: High-throughput screening for evidence of association by using mass spectrometry genotyping on DNA pools. Proc Natl Acad Sci U S A 2002, 99(26):16928-16933.
20. Kammerer S, Langdown M, Roth R, Mah S, Hoyal C, Marnellos G, Reneland R, Nelson M, Braun A: Systematic Identification of Disease-Related Genes.2003 [http://www.sequenom.com/Assets/pdfs/posters].
21. Williams NG, Roberts TM: Signal transduction pathways involving the Raf proto-oncogene. Cancer Metastasis Rev 1994, 13(1):105-116.
22. Pruitt KD, Maglott DR: Locus Link. 2003 [http://www.ncbi.nlm.nih.gov/LocusLink/LocRpt.cgi?l=673].
23. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S, Hooper S, Wilson R, Jayatilake H, Gusterson BA, Cooper C, Shipley J, Hargrave D, Pritchard-Jones K, Maitland N, Chenevix-Trench G, Riggins GJ, Bigner DD, Palmieri G, Cossu A, Flanagan A, Nicholson A, Ho JW, Leung SY, Yuen ST, Weber BL, Seigler HF, Darrow TL, Paterson H, Marais R, Marshall CJ, Wooster R, Stratton MR, Futreal PA: Mutations of the BRAF gene in human cancer. Nature 2002, 417(6892):949-954.
24. Lang J, Boxer M, MacKie R: Absence of exon 15 BRAF germline mutations in familial melanoma. Hum Mutat 2003, 21(3):327-330.
25. Laud K, Kannengiesser C, Avril MF, Chompret A, Stoppa-Lyonnet D, Desjardins L, Eychene A, Demenais F, Lenoir GM, Bressac-de Paillerets B: BRAF as a melanoma susceptibility candidate gene? Cancer Res 2003, 63(12):3061-3065.
26. Meyer P, Klaes R, Schmitt C, Boettger MB, Garbe C: Exclusion of BRAFV599E as a melanoma susceptibility mutation. Int J Cancer 2003, 106(1):78-80.
27. Cohen Y, Xing M, Mambo E, Guo Z, Wu G, Trink B, Beller U, Westra WH, Ladenson PW, Sidransky D: BRAF mutation in papillary thyroid carcinoma. J Natl Cancer Inst 2003, 95(8):625-627.
28. Fukushima T, Suzuki S, Mashiko M, Ohtake T, Endo Y, Takebayashi Y, Sekikawa K, Hagiwara K, Takenoshita S: BRAF mutations in papillary carcinomas of the thyroid. Oncogene 2003, 22(41):6455-6457.
29. Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE, Fagin JA: High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTCRAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res 2003, 63(7):1454-1457.
30. Namba H, Nakashima M, Hayashi T, Hayashida N, Maeda S, Rogounovitch TI, Ohtsuru A, Saenko VA, Kanematsu T, Yamashita S: Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers. J Clin Endocrinol Metab 2003, 88(9):4393-4397.
31. Xu X, Quiros RM, Gattuso P, Ain KB, Prinz RA: High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines. Cancer Res 2003, 63(15):4561-4567.
32. Brose MS, Volpe P, Feldman M, Kumar M, Rishi I, Gerrero R, Einhorn E, Herlyn M, Minna J, Nicholson A, Roth JA, Albelda SM, Davies H, Cox C, Brignell G, Stephens P, Futreal PA, Wooster R, Stratton MR, Weber BL: BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res 2002, 62(23):6997-7000.
33. Naoki K, Chen TH, Richards WG, Sugarbaker DJ, Meyerson M: Missense mutations of the BRAF gene in human lung adenocarcinoma. Cancer Res 2002, 62(23):7001-7003.
34. Rajagopalan H, Bardelli A, Lengauer C, Kinzler KW, Vogelstein B, Velculescu VE: Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status.Nature 2002, 418(6901):934.
35. Wang L, Cunningham JM, Winters JL, Guenther JC, French AJ, Boardman LA, Burgart LJ, McDonnell SK, Schaid DJ, Thibodeau SN: BRAF mutations in colon cancer are not likely attributable to defective DNA mismatch repair. Cancer Res 2003, 63(17):5209-5212.
36. Yuen ST, Davies H, Chan TL, Ho JW, Bignell GR, Cox C, Stephens P, Edkins S, Tsui WW, Chan AS, Futreal PA, Stratton MR, Wooster R, Leung SY: Similarity of the phenotypic patterns associated with BRAF and KRAS mutations in colorectal neoplasia. Cancer Res 2002, 62(22):6451-6455.
37. Buetow KH, Edmonson M, MacDonald R, Clifford R, Yip P, Kelley J, Little DP, Strausberg R, Koester H, Cantor CR, Braun A: High-throughput development and characterization of a genomewide collection of gene-based single nucleotide polymorphism markers by chip-based matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Proc Natl Acad Sci U S A 2001, 98(2):581-584.
38. Stephens M, Smith NJ, Donnelly P: A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 2001, 68(4):978-989.